Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282138 · ClinicalTrials.gov registry record · Phase 4
Assessment of Alcon's Ocular Image Quantification System
A Phase 4 study of Allergic Conjunctivitis, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT01282138: Completed Phase 4 study of Allergic Conjunctivitis, sponsored by Alcon Research.
NCT01282138 is a Phase 4 study of Allergic Conjunctivitis that has completed, run by Alcon Research. The registered enrollment target is 13 participants, below the 134-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01282138, a Phase 4 study of Allergic Conjunctivitis, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study was to evaluate ocular responses with different allergen provocation methods.
Primary Outcome
As assessed by the participant after 3 hours in the EEC. Ocular itching was graded on a 0-4 scale, where 0=none, 1=tickling sensation involving one or more corners of the eye, 2=all over tickling sensation; 3=moderate continuous itching with desire to rub; 4=severe itching with irresistible urge to rub.
Conditions Studied
Interventions
- DRUG Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
- OTHER Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)
Study Locations (1)
Texas
- Contact Alcon Call Center for Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-03 |
| Phase | Phase 4 |
What the finished NCT01282138 record still lists
NCT01282138 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 134-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol) is the first listed.
NCT01282138 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01282138 about?
NCT01282138 is a clinical study titled "Assessment of Alcon's Ocular Image Quantification System". The purpose of this study was to evaluate ocular responses with different allergen provocation methods.
What is the current status of trial NCT01282138?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2010-12. Estimated completion is 2011-03.
What conditions does trial NCT01282138 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT01282138?
The interventions under investigation include: Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol) (DRUG), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II) (OTHER).
Who is sponsoring clinical trial NCT01282138?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01282138 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01282138's enrollment target sits among peer trials
13 20th of 20 higher than 1 of 20 other Allergic Conjunctivitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Conjunctivitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
COMPLETED · Phase 4
-
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
COMPLETED · Phase 4
-
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
COMPLETED · Phase 4
-
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
COMPLETED · Phase 4
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia